Teva- Pharmaceutical Industries EBIT

The latest EBIT for TEVA is $1.8B as of June 2026. That compares with $540M in the prior-year period — up 239.8% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Teva- Pharmaceutical Industries's historical trend and sector peers before judging valuation or financial health.

Over the past year, TEVA's EBIT moved from $540M to $1.8B — a 239.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Teva- Pharmaceutical Industries's operating scale or balance-sheet position.

Against Healthcare companies, TEVA currently prints $1.8B for EBIT, while the sector average sits near $110B. That is roughly 98.3% below the sector mean. Large gaps often invite a closer look at Teva- Pharmaceutical Industries's growth, margins, and balance sheet.

A EBIT figure of $1.8B for TEVA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting TEVA's EBIT ($1.8B), review year-over-year change from $540M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.